Heska (NASDAQ:HSKA) and Arca Biopharma (NASDAQ:ABIO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.
Risk & Volatility
Heska has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Arca Biopharma has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500.
This table compares Heska and Arca Biopharma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
89.0% of Heska shares are owned by institutional investors. Comparatively, 18.8% of Arca Biopharma shares are owned by institutional investors. 14.0% of Heska shares are owned by insiders. Comparatively, 3.6% of Arca Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This is a summary of current ratings and recommmendations for Heska and Arca Biopharma, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Heska presently has a consensus price target of $76.67, suggesting a potential upside of 5.35%. Arca Biopharma has a consensus price target of $17.00, suggesting a potential upside of 230.74%. Given Arca Biopharma’s stronger consensus rating and higher possible upside, analysts clearly believe Arca Biopharma is more favorable than Heska.
Earnings & Valuation
This table compares Heska and Arca Biopharma’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Heska||$127.45 million||4.45||$5.85 million||$1.42||51.25|
|Arca Biopharma||N/A||N/A||-$7.93 million||N/A||N/A|
Heska has higher revenue and earnings than Arca Biopharma.
Heska beats Arca Biopharma on 7 of the 10 factors compared between the two stocks.
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps. It also provides digital radiography hardware and mobile digital radiography products, as well as ultrasound systems; Cloudbank, a Web-based image storage solution; ViewCloud, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. The company's Other Vaccines and Pharmaceuticals segment offers a line of bovine vaccines; biological and pharmaceutical products for other animal health companies; and various turnkey services comprising research, licensing, production, labeling, and packaging, as well as provides validation support and distribution services. Heska Corporation sells its products to veterinarians through a field organization, a telephone sales force, and third party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is headquartered in Loveland, Colorado.
About Arca Biopharma
ARCA biopharma, Inc. is a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). The company also engages in the development of a preclinical plan for AB171, a new chemical entity for the treatment of various cardiovascular indications, such as peripheral arterial disease and chronic HF. It has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B clinical trials; and Laboratory Corporation of America to provide the companion diagnostic test and services to support GENETIC-AF trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.